key: cord-0772116-l0rk37zb
authors: Holzhauser, Luise; Lourenco, Laura; Sarswat, Nitasha; Kim, Gene; Chung, Ben; Nguyen, Ann B.
title: Early experience of COVID‐19 in 2 heart transplant recipients: Case reports and review of treatment options
date: 2020-05-22
journal: Am J Transplant
DOI: 10.1111/ajt.15982
sha: 1301153495e04a381d05ca7489044aaf07f20116
doc_id: 772116
cord_uid: l0rk37zb

The coronavirus disease 2019 (COVID‐19) pandemic poses special challenges to immunocompromised transplant patients. Given the paucity of proven data in treating COVID‐19, management of these patients is difficult, rapidly evolving, and mainly based on anecdotal experience. We report 2 cases of heart transplant (HT) recipients with COVID‐19. The first is a 59‐year‐old female with HT in 2012 who presented on March 20, 2020 with fever, hypoxia, and ground‐glass opacities on chest X‐ray. She quickly progressed to acute hypoxic respiratory failure and vasoplegic shock. Despite reduction in immunosuppression and treatment with tocilizumab, intravenous immunoglobulin, hydroxychloroquine, lopinavir/ritonavir, and broad‐spectrum antibiotics, she ultimately died from multiorgan failure. The second case is a 75‐year‐old man with HT in 2000 who presented on April 2, 2020 after curbside testing revealed positive COVID‐19. Given a milder presentation compared to the first patient, antimetabolite was discontinued and only hydroxychloroquine was started. Because of a lack of clinical improvement several days later, tocilizumab, methylprednisolone, and therapeutic anticoagulation were initiated. The patient clinically improved with decreasing oxygen requirements and was discharged home. These 2 cases highlight the wide range of different presentations of COVID‐19 in HT recipients and the rapidity with which the management of these patients is evolving.

She presented on March 20, 2020 with fever, myalgia, fatigue, diarrhea, productive cough, and shortness of breath for 3 days.

Temperature was 38.8C, heart rate 108 bpm, blood pressure 120/90mm Hg, respiratory rate 25, and oxygen saturation 92% on 3L nasal cannula (NC). Notable laboratory values include interleukin (IL)-6 62.7 pg/mL, immunoglobulin G (IgG) 1426 mg/dL, tacrolimus trough 8.5 ng/mL, and creatinine (Cr) 2.6 mg/dL (baseline 1.8- [1] [2] [3] [4] and tocilizumab 400 mg intravenous (1 dose) were initiated. Antibiotic coverage was broadened to include doxycycline. A single dose of intravenous immunoglobulin (IVIG) 10g was given but not continued after a normal IgG level returned. Underlying CKD precluded enrollment into a remdesivir trial (excluded if CrCl < 50 mL/min). As a second option, antiviral therapy with lopinavir/ritonavir 400 mg twice daily for 5 days was added.

Consideration was given to drug-drug interactions with tacrolimus.

She initially improved on day 1 and was transitioned to NC.

However, she subsequently developed worsening renal failure and acute respiratory distress syndrome (ARDS, Figure 1 , right). She was intubated on day 2 and started on continuous veno-venous hemodialysis (CVVHD). ABG at this time showed pH 7.25, pCO 2 30mm Hg, pO 2 59 mm Hg on FiO 2 0.8, and tacrolimus trough was 7.0 ng/mL. She required norepinephrine for vasoplegic shock and antifungal coverage with micafungin 100mg daily was added.

Despite decreasing C-reactive protein, other inflammatory markers including ferritin, d-dimer, and creatinine kinase continued to uptrend (Table 1) . High sensitivity troponin (Hs-Tn) remained stable and bedside echocardiogram showed preserved graft function. On days 3 and 4, low tidal volume ventilation was continued with FiO 2 0.6 and PEEP 18mmH 2 O, and on day 5, the patient was prone positioned. Given tacrolimus trough of 6.7 ng/mL, 1 dose of tacrolimus with 60% dose reduction was given, however because of rapidly rising levels, it was held thereafter. On day 7, given rising white blood count and markedly elevated fungitell assay (259 pg/mL, <60 pg/ mL), sulfamethoxazole-trimethoprim-DS was started for presumed pneumocystis jirovecii pneumonia. At this point, veno-venous extracorporeal membrane oxygenation (VV-ECMO) was considered for progressive ARDS; however, the difficult decision was made not to offer VV-ECMO due to age, comorbidities, and poor prognosis.

Heparin drip was started as the CVVHD line was clotting with rising d-dimer levels. Tobramycin and linezolid were given for worsening leukocytosis. On day 10, the patient's family was notified of her grave prognosis and care was withdrawn.

The patient is a 75-year-old man with history of ischemic cardio- Table 2 . Chest X-ray showed chronic lung disease with overlying opacities on the left suspicious for atypical infection ( Figure 2 , left). Upon admission, MMF was held and CSA was continued at home dose. Despite a mild presentation, hydroxychloroquine was initiated because of age and comorbidities.

On days 1-4, the patient remained febrile and nauseated. He was hemodynamically stable and did not require supplemental oxygen.

On the evening of the fourth day, he become hypoxic with oxygen saturation of 85% on 2L NC, requiring nonrebreather with improvement to 98%.

Chest X-ray showed increase in basilar interstitial markings ( Figure 2 , right). Over several hours, he was weaned to 2L NC. Given clinical decompensation, the decision was made on day 5 to give tocilizumab 400mg intravenous (1 dose) and methylprednisolone 40mg intravenous daily for 5 days and to increase lovenox from prophylactic to treatment dosing. He subsequently improved and was discharged on day 8. Emerging clinical evidence and available in vitro data suggest remdesivir is a promising antiviral agent for treatment of SARS-CoV-2 . [11] [12] [13] [14] Remdesivir acts as an RNA chain terminator that displays high genetic barrier to resistance in coronaviruses. 15, 16 Although remdesivir is a substrate for cytochrome P450 enzymes, its metabolism is mediated by hydrolase activity, thus avoiding significant drug interactions with CYP3A4 inhibitors or inducers, 16 The compelling mortality difference in SARS-CoV-1 and continued investigation in MERS-CoV led to inclusion of LPV/r in the Chinese SARS-CoV-2 guidelines at a dose of 400mg/100mg twice daily for no more than 10 days. 22 Notably, in a recent randomized controlled trial in COVID-19 pneumonia, there was no benefit seen with LPV/r; however, the median time from symptom onset to initiation of therapy was 13 days, and in the SARS-CoV-1 experience, therapy appeared effective if started early. 23 It is important to note that protease inhibitors such as ritonavir are potent inhibitors of the metabolism of immunosuppressive drugs including calcineurin inhibitors (CNI) and must be used with caution in transplant patients. 24 As CNI are known to affect kidney function, close monitoring is imperative when given with LPV/r, especially in light of observed acute kidney injury in COVID-19 patients and adverse effects on mortality. 25, 26 In our first case, during the course of treatment with LPV/r, daily tacrolimus troughs ranged from 6-8 ng/ mL and was 7 ng/mL at the time of initiation of CVVHD on day 2. increase in basilar interstitial markings T cell-mediated detrimental immune system overactivation and could diminish acute lung injury observed in COVID-19. [27] [28] [29] It is interesting to note that in the 2 cases reported in China and our patients, all were on relatively low doses of baseline immunosuppression, potentially supporting this hypothesis. 3 Much more data are needed to confirm or dismiss this hypothesis.

Aside from the potential benefit of immunosuppression in the well-described cytokine storm of COVID-19, anti-inflammatory treatment options are also available. We used tocilizumab in both of our cases to counteract the hyperinflammatory state and cytokine storm associated with increased mortality in COVID-19 patients in China. 30 Tocilizumab is a humanized monoclonal antibody that inhibits IL-6 receptors. IL-6 is one of the main drivers of the immunologic response in patients with cytokine-release syndrome. Immunotherapy with tocilizumab is part of the Chinese COVID-19 Diagnosis and Treatment Guide (400 mg IV once, option to repeat at 12 hours for max of 800 mg). 22 A Chinese case series of 21 patients treated with tocilizumab reported rapid resolution of fever and C-reactive protein, decreased oxygen requirements, and resolution of lung opacities without adverse events. 31 Optimal timing of tocilizumab administration is not yet defined.

Similar to other severe respiratory tract infections, there is significant controversy surrounding the role of corticosteroids for management of severe pneumonia due to coronaviruses. The potential benefit of steroids, which is to blunt the inflammatory cascade seen in severe disease, needs to be carefully weighed against the concerns for secondary infections and adverse events of corticosteroid therapy. In MERS-CoV, corticosteroids was associated with delayed time to viral clearance. 9 However, recent evidence in SARS-CoV-2 suggested a decrease in mortality in patients with ARDS with use of corticosteroids. 32 Thus, steroids must be considered carefully but could be helpful in the postviremic hyperinflammatory phase. 10 A consensus statement from the Chinese Thoracic Society recommends ≤ 0.5-1 mg/kg/day methylprednisolone for ≤ 7 days in select patients, after careful consideration of risks. 33 In contrast to a reported COVID-19 HT case from China with a milder course, we opted to not use steroids in our first patient case given long-standing immunosuppression and fear of delayed viral clearance. 34 We revised this strategy in the management of our second patient by initiating methylprednisolone 0.5 mg/kg/day as recommended by the Chinese Thoracic Society. Following treatment with tocilizumab and steroids, oxygen requirements decreased.

A phenomenon observed in COVID-19 patients is high incidence of thrombotic events suggesting a disease-specific coagulopathic state.

In severe cases, use of anticoagulation with heparin has been shown to decrease mortality. 4, 35, 36 The evidence for anticoagulation has accumulated following the death of our first patient, who received prophylactic dosing of heparin. For our second patient, we opted for empiric therapeutic anticoagulation following worsening hypoxia and rising d-dimer levels. We cannot rule out the possibility of pulmonary embolism (PE) as a contributor to our first patient's decompensation; however, Hs-Tn levels remained stable at a low level, decreasing suspicion for a hemodynamically significant PE. Our second patient improved significantly following treatment with steroids, tocilizumab, and therapeutic anticoagulation and was discharged home. 

The appropriate management of SARS-CoV-2 is a rapidly evolving therapeutic challenge and optimal strategy remains unknown, particularly for the critically ill and special populations. It is prudent to quickly initiate supportive therapy with consideration of additional measures for high-risk populations. Importantly, this strategy is not without risk and needs to be weighed against potential adverse events, which remain poorly defined. Another pressing issue is impending drug shortages with increases in use of these agents and disruptions in supply chain. Caution should be applied, as available clinical data are largely uncontrolled, not peer reviewed, or still unpublished.

It is of utmost interest to focus on improving our understanding of the pathophysiology and treatment of COVID-19. Thus, we believe it is essential for clinicians to report their experiences treating COVID-19 in transplant recipients so we may further optimize treatment options.

The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

Luise Holzhauser https://orcid.org/0000-0001-7908-4611

An interactive web-based dashboard to track COVID-19 in real time

Epidemiological and clinical characteristics of heart transplant recipients during the 2019 coronavirus outbreak in Wuhan, China: a descriptive survey report

First cases of COVID-19 in heart transplantation from China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Mass General Hospital #COVID19 #CriticalCare Treatment Guide

Laboratory abnormalities in patients with COVID-2019 infection

Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study

A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication

Corticosteroid therapy for critically Ill patients with middle east respiratory syndrome

COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease

Discovery and synthesis of a phosphoramidate prodrug of a Pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of ebola and emerging viruses

First 12 patients with coronavirus disease 2019 (COVID-19) in the United States. medRxiv

Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Chloroquine and hydroxychloroquine as available weapons to fight COVID-19

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

Health National Commission (NHC) of the People's Republic of China. The diagnosis and treatment guide of COVID-19 pneumonia caused by new coronavirus infection

A trial of Lopinavir-Ritonavir in adults hospitalized with severe covid-19

Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients

Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients

Kidney disease is associated with in-hospital death of patients with COVID-19

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Immunosuppression drug-related and clinical manifestation of Coronavirus disease 2019: a therapeutical hypothesis

COVID-19: yet another coronavirus challenge in transplantation

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Effective treatment of severe COVID-19 patients with tocilizumab

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

On the use of corticosteroids for 2019-nCoV pneumonia

First cases of COVID-19 in heart transplantation from China

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis

Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19

Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19

Early experience of COVID-19 in two heart transplant recipients: Case reports and review of treatment options